Cadila Pharmaceuticals Ltd

About the Company :

Cadila Pharmaceuticals Limited was founded in 1951, by Late Mr. Indravadan I. Modi and Late Mr. Ramanbhai B. Patel. Subsequently, in 1995, it was bifurcated into two different companies namely Cadila Healthcare Limited, part of Patel group and Cadila, part of Modi group. Cadila manufactures both formulations and API drugs for more than 45 therapeutic areas.

The company has two API manufacturing facilities located at Ankleshwar (Gujarat), one formulation facility at Dholka (Gujarat) which is USFDA approved and one formulation facility at Samba in Jammu. Cadila also has state of art R&D centre at Dholka. Cadila also has formulation facilities in Ethiopia through its 57.50% Joint Venture (JV). Cadila exports its products to various countries through its marketing set up in USA, Japan, Africa and Russia. Currently, Cadila is ranked 26th with around 0.96% market share in the Indian Pharmaceuticals Market

Cadila Healthcare receives USFDA approval for Haloperidol Decanoate injection

Cadila Healthcare has received USFDA approval for Haloperidol Decanoate injection used in treatment of schizophrenia. It is also used in ...

Read More

Cadila group receives USFDA approval for Ranolazine Extended-Release

Zydus Cadila has received final USFDA approval to market generic Ranolazine Extended-Release tablets used for treatment of chronic angina in ...

Read More

Cadila Pharma receives GLPC certification for its Dholka facility

Cadila Pharma has received the Good Laboratory Practices Certification (GLP) from National Good Laboratory Practice compliance Monitoring Authority (NGCMA), Department ...

Read More

Cadial receives USFDA approval for Chlorthalidone

Zydus Cadila has received final USFDA to market Chlorthalidone tablets, used to treat high blood pressure. The drug will be ...

Read More

Cadila receives USFDA approval for Ambrisentan

Zydus Cadila has received final USFDA approval to market Ambrisentan tablets in in strengths of 5 mg and 10 mg ...

Read More

Cadila receives USFDA approval for potassium chloride extended release tablets

Cadila has received USFDA approval for Potassium Chloride extended-release capsules to market the same in United States. The product is ...

Read More

Cadila receives USFDA approval for Acetazolamide ER

Zydus Cadila has received the final USFDA approval to market Acetazolamide ER Capsules. Acetazolamide is a potent carbonic anhydrase inhibitor ...

Read More

Cadila receives USFDA approval for Aripiprazole

Cadila has received final USFDA approval to market antipsychotic drug Aripiprazole tablets in US markets. The drug will be marketed ...

Read More

Cadila Group has received USFDA approval for Doxycycline Hyclate and Febuxostat

Zydus Cadila has received final USFDA approval to market Doxycycline Hyclate delayed-release tablets which are used to treat bacterial infections ...

Read More

Zydus Cadila receives USFDA approval for Lansoprazole

Zydus Cadila has received final USFDA approval to market generic Lansoprazole delayed release orally disintegrating tablets in the strengths of ...

Read More